The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia

• Status: Recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate that whether the AML (acute myeloid leukemia)-CAMS (Chinese Academy of Medical Sciences)-2016 regimen, includes risk-stratified therapy and the use of Dasatinib in CBF (Core binding factor)-AML, can improve the outcome in childhood AML.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Institute of Hematology & Blood Diseases Hospital
• Treatments: Aclacinomycins; Cytarabine; Dasatinib; Etoposide; Idarubicin; Lenograstim; Mitoxantrone; Sargramostim

Criteria

Inclusion Criteria:

• Newly diagnosis of de novo Acute Myeloid Leukemia

Exclusion Criteria:

• Children with Down's syndrome and acute promyelocytic leukemia, hybrid acute leukemia